4503 — Astellas Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual cashflow statement for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	245,350	145,324	156,886	132,361	24,969
Depreciation
Non-Cash Items	12,437	91,075	73,650	85,167	79,480
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-102,186	-2,208	-52,777	4,501	-89,813
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities	221,997	306,843	257,443	327,767	172,476
Capital Expenditures	-77,888	-77,441	-76,448	-88,541	-82,497
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-311,905	-4,453	14,035	4,041	-763,305
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-389,793	-81,894	-62,413	-84,500	-845,802
Financing Cash Flow Items	-847	-2,268	-2,530	-3,217	-16,539
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	181,055	-229,479	-216,298	-195,623	614,060
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	7,317	7,737	-10,143	60,854	-41,153